Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

Key value for chemical safety assessment

Additional information

A documentation and evaluation of available data on this endpoint is presented in:

Thiodiglycol, SIDS Initial Assessment Report for SIAM 19, final version 10/2006.

No quantitative data are available on the absorption from the gastrointestinal tract, or on the absorption after inhalation exposure. In in vitro experiments using pig skin the percutaneous absorption was 20% after application of radiolabelled thiodiglycol in acetone solution (Reifenrath et al., 2002).

Metabolism and excretion after i.p. injection was studied in male Porton rats (Black et al., 1993). For the determination of the excretion profile, rats received i.p. 35S-radiolabed thiodiglycol at doses of 24 µg/kg bw to 40 mg/kg bw. Ca. 60 % of the administered dose was excreted via urine within 6 hours, ca. 90 % within 24 hours and virtually all of the dose within 8 days (93 - 99 %), independently of the amount injected. No significant excretion was detected in the faeces.

For isolation and identification of metabolites, rats were i.p. injected with 40 mg/kg bw doubly labelled 13C4,35S-thiodiglycol. Samples of pooled urine were analyzed 6 and 24 hours after injection and then daily for 8 days. Thiodiglycol sulphoxide was the major metabolite (oxidation at the sulphur atom) accounting for ca. 90 % of the excreted radioactivity. S-(2-hydroxyethylthio) acetic acid was present in significant quantities up to 10 %; thiodigylcol sulphone and S-(2- hydroxyethylsulphinyl)acetic acid were identified as minor metabolites. Only 0.5 - 1.0 % of the administered dose was excreted unmetabolized.